Business News

India based Hetero to produce over 100 million Sputnik V vaccine in India

On Friday, one of Russia’s Sputnik V corona virus vaccine developer announced that Hetero which India Based drugmaker will be producing over 100million doses of the vaccine.

“Hetero, one of India’s leading generic pharmaceutical companies, have agreed to produce in India over 100 million doses per year of the world’s first registered vaccine against the novel coronavirus infection — Sputnik V,” the Russian Direct Investment Fund (RDIF) said in their statement

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. With over 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Generics, Biosimilars, Custom Pharmaceutical Services and Branded Generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, audited and approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa and others. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.

India based Hetero to produce over 100 million Sputnik V vaccine in India

Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.

“We are delighted to announce the agreement between RDIF and Hetero that will pave the way to the production of the safe and highly effective Sputnik V vaccine on Indian soil. The vaccine’s interim clinical trial results show 95 per cent efficacy on the 42nd day after the first dose,” read the statement on Sputnik V Twitter account.

“I am confident that Sputnik V should become an integral part of the national vaccine portfolio of every country willing to protect its population from the coronavirus. Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity and provide people of India with an efficient solution in this challenging period of the pandemic,” said Kirill Dmitriev, CEO of the RDIF .

RDIF and Hetero hope to start producing the Vaccine in the beginning of 2021.

Recently Russia said that the interim results of the vaccine from the clinical results showed 95 per cent effectiveness. It is similar to several other vaccines whose test results have shown effective results of above 90 percent.

Russia was the first country to announce the registeration of the first ever corona virus vaccination .back in August.The trials are underway at the third and final phase with around 40 thousand volunteers involved in blind testing of the Sputnik V vaccine

Russia announced that the Vaccine will cost $10Per dose in the international markets,which is relatively less than other registered COVID-19 vaccines

Read Also: Moderna vaccine is 95% effective